Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Sarcoma 2Thoracic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 134Carcinoma, Renal Cell 51Kidney Neoplasms 42Leukemia, Myeloid, Acute 38Neoplasm Metastasis 37Leukemia 33Lymphoma 30Breast Neoplasms 26Ovarian Neoplasms 24Lymphoma, Non-Hodgkin 22Carcinoma, Non-Small-Cell Lung 22Skin Neoplasms 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Neuroblastoma 18Lymphoma, Follicular 18Pancreatic Neoplasms 16Lymphoma, Mantle-Cell 16Leukemia, Lymphocytic, Chronic, B-Cell 16Stomach Neoplasms 14Neoplasms 14Myelodysplastic Syndromes 14Colorectal Neoplasms 13Multiple Myeloma 12Lymphoma, Large B-Cell, Diffuse 12Lymphoma, B-Cell, Marginal Zone 12Hodgkin Disease 12Congenital Abnormalities 12Uterine Cervical Neoplasms 11Lymphoma, Large-Cell, Immunoblastic 11Lung Neoplasms 11

Interventions

Magnetic Resonance Spectroscopy 16Hydroxyurea 7Everolimus 7Bevacizumab 7lutetium Lu 177 dotatate 6gallium Ga 68 dotatate 6Proton Therapy 6Specimen Handling 5pembrolizumab 4Surgical Procedures, Operative 4Radiosurgery 4Imatinib Mesylate 4Cyclophosphamide 42-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 4aldesleukin 3abemaciclib 3Tranexamic Acid 3Temozolomide 3Sunitinib 3Sodium Chloride 3Radiotherapy, Intensity-Modulated 3Radiotherapy 3Nivolumab 3Ga(III)-DOTATOC 390Y-octreotide, DOTA-Tyr(3)- 3vistusertib 2trametinib 2ribociclib 2fludarabine 2arginyllysine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Meningioma × aldesleukin × Clear all
NCT01967823 2021-03-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
11 enrolled 12 charts
BreastCNSDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Meningioma, Neoplasm Metastasis

NCT01082926 2015-06-08

Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2

City of Hope Medical Center

Phase 1 Completed
6 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Meningioma, Oligodendroglioma, Neuroectodermal Tumors, Primitive, Gliosarcoma

NCT00014573 2013-04-08

Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
CNSSarcoma

Familial ependymoma, Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Neuroectodermal Tumors, Primitive, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡